Capital Flow Monitor · Sponsors · CIK 1853373
Kestrel Therapeutics Inc.
Attn: Pagliuca Harvard Life Lab, Boston, MA, 02134 · 617-460-3772
Biotechnology · Corporation· inc. DELAWARE true 2020
Fit score
—
Offering
$10.0M
Sold
$5.0M
% sold
50.0%
Investors
6
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2025-08-12 | D ·current | 506(b) | $10.0M | $5.0M | 50.0% | 6 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- Frank G. Haluska — Executive Officer / Director, Boston, MA
- Denis Patrick — Director, Boston, MA
- Omar Khalil — Director, Boston, MA
-
Andrew Phillips — Director, Boston, MA
2 other raises
- LiquidX, Inc. $4.6M of $5.7M · 80.6%
- Nexo Therapeutics, Inc. $60.0M of $60.0M · 100.0%
-
Nicholas Saccomano — Director, Boston, MA
1 other raise
- BioLoomics, Inc. $450K of $2.0M · 22.5%
- Barbara Sosnowski — Director, Boston, MA
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.